Insider Transaction Report for Jennifer Riley

Jennifer Riley, Chief Strategy Officer of Avalo Therapeutics, Inc. (AVTX), reported a transaction involving 34,200 shares of Common Stock on May 21, 2026. These shares were acquired through performance stock units (PSUs) granted on August 19, 2025, with the achievement of performance goals certified on May 21, 2026. The PSUs are set to fully vest on August 19, 2028, contingent upon Riley's continued service. Following this transaction, Riley holds 36,855 shares. The transaction code is "A" and the ownership nature is "Direct".